Viewing Study NCT04382157


Ignite Creation Date: 2025-12-24 @ 6:38 PM
Ignite Modification Date: 2025-12-24 @ 6:38 PM
Study NCT ID: NCT04382157
Status: UNKNOWN
Last Update Posted: 2021-09-28
First Post: 2020-05-03
Is Possible Gene Therapy: False
Has Adverse Events: False

Brief Title: Magnesium Replacement and Hyperglycemia After Kidney Transplantation
Sponsor: Oslo University Hospital
Organization:

Study Overview

Official Title: Magnesium Replacement and Hyperglycemia After Kidney Transplantation
Status: UNKNOWN
Status Verified Date: 2021-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The insulin receptor is dependent on magnesium and hypomagnesemia is associated with increased insulin resistance and decreased insulin secretion and action. Recent data suggest that hypomagnesemia may play a role in development of type 2 diabetes. Kidney transplantation patients have low plasma magnesium levels, partly due to treatment with calcineurin inhibitors. However, the role of magnesium in the development of post-transplant diabetes mellitus (PTDM) is unclear.

The present study addresses, whether hypomagnesemia is feasible to reverse by oral administration of magnesium.

The investigators wish to investigate whether oral magnesium supplementation is sufficient to increase magnesium levels in kidney transplant recipients, and if supplementation improves glycemic parameters as measured by an oral glucose tolerance test (OGTT).
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: